Effects of Statin Treatment on Outcomes after Traumatic Brain Injury

John Whyte, Jessica M. Ketchum, Jenny Bogner, Robert C. Brunner, Flora Hammond, Ross Zafonte, Gale G. Whiteneck, Alan Weintraub

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Neuroprotective treatments that have shown promise in reducing secondary injury and improving recovery in animal models of traumatic brain injury (TBI) have not been found effective to date in humans. One reason may be the delay after injury in initiating treatment. Statin medications are among the promising neuroprotective agents in animal models, and their presence in the bloodstream of many individuals at the time of injury might optimize their clinical impact. This observational study conducted by a subset of centers participating in the National Institute on Disability, Independent Living, and Rehabilitation Research (NIDILRR)-funded TBI Model System program sought to examine the effects of taking statin medication at the time injury on functional outcomes. Participants >50 years of age were prospectively enrolled during patient rehabilitation. Demographic data, cardiovascular history, and brain injury history were obtained through chart abstraction and interview. Prescription medication use in the year prior to enrollment was determined from a national pharmacy search service. Propensity scoring was used to create 49 pairs of participants who were well matched on demographic and clinical attributes but discordant for statin use. The treated and untreated participants did not differ on initial Glasgow Coma Score, time until commands were followed, duration of post-traumatic amnesia, or Functional Independence Measure (FIM) scores at rehabilitation admission, discharge, or 1 year post-injury, or on acute or rehabilitation hospital lengths of stay. Evidence of greater and lesser statin compliance was not associated with outcome. This study did not provide support for a clinically important benefit of statin use at the time of moderate to severe TBI.

Original languageEnglish (US)
Pages (from-to)118-125
Number of pages8
JournalJournal of Neurotrauma
Volume36
Issue number1
DOIs
StatePublished - Jan 1 2019

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Wounds and Injuries
Rehabilitation
Length of Stay
Animal Models
Demography
Independent Living
Pharmaceutical Services
Amnesia
Neuroprotective Agents
Coma
Brain Injuries
Compliance
Observational Studies
Prescriptions
History
Traumatic Brain Injury
Interviews
Therapeutics

Keywords

  • brain injuries
  • hydroxymethylglutaryl-CoA reductase inhibitors
  • neuroprotection
  • propensity score
  • treatment outcome

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Whyte, J., Ketchum, J. M., Bogner, J., Brunner, R. C., Hammond, F., Zafonte, R., ... Weintraub, A. (2019). Effects of Statin Treatment on Outcomes after Traumatic Brain Injury. Journal of Neurotrauma, 36(1), 118-125. https://doi.org/10.1089/neu.2017.5545

Effects of Statin Treatment on Outcomes after Traumatic Brain Injury. / Whyte, John; Ketchum, Jessica M.; Bogner, Jenny; Brunner, Robert C.; Hammond, Flora; Zafonte, Ross; Whiteneck, Gale G.; Weintraub, Alan.

In: Journal of Neurotrauma, Vol. 36, No. 1, 01.01.2019, p. 118-125.

Research output: Contribution to journalArticle

Whyte, J, Ketchum, JM, Bogner, J, Brunner, RC, Hammond, F, Zafonte, R, Whiteneck, GG & Weintraub, A 2019, 'Effects of Statin Treatment on Outcomes after Traumatic Brain Injury', Journal of Neurotrauma, vol. 36, no. 1, pp. 118-125. https://doi.org/10.1089/neu.2017.5545
Whyte, John ; Ketchum, Jessica M. ; Bogner, Jenny ; Brunner, Robert C. ; Hammond, Flora ; Zafonte, Ross ; Whiteneck, Gale G. ; Weintraub, Alan. / Effects of Statin Treatment on Outcomes after Traumatic Brain Injury. In: Journal of Neurotrauma. 2019 ; Vol. 36, No. 1. pp. 118-125.
@article{6f63f174bef9493bb0ac62a2d240ee8a,
title = "Effects of Statin Treatment on Outcomes after Traumatic Brain Injury",
abstract = "Neuroprotective treatments that have shown promise in reducing secondary injury and improving recovery in animal models of traumatic brain injury (TBI) have not been found effective to date in humans. One reason may be the delay after injury in initiating treatment. Statin medications are among the promising neuroprotective agents in animal models, and their presence in the bloodstream of many individuals at the time of injury might optimize their clinical impact. This observational study conducted by a subset of centers participating in the National Institute on Disability, Independent Living, and Rehabilitation Research (NIDILRR)-funded TBI Model System program sought to examine the effects of taking statin medication at the time injury on functional outcomes. Participants >50 years of age were prospectively enrolled during patient rehabilitation. Demographic data, cardiovascular history, and brain injury history were obtained through chart abstraction and interview. Prescription medication use in the year prior to enrollment was determined from a national pharmacy search service. Propensity scoring was used to create 49 pairs of participants who were well matched on demographic and clinical attributes but discordant for statin use. The treated and untreated participants did not differ on initial Glasgow Coma Score, time until commands were followed, duration of post-traumatic amnesia, or Functional Independence Measure (FIM) scores at rehabilitation admission, discharge, or 1 year post-injury, or on acute or rehabilitation hospital lengths of stay. Evidence of greater and lesser statin compliance was not associated with outcome. This study did not provide support for a clinically important benefit of statin use at the time of moderate to severe TBI.",
keywords = "brain injuries, hydroxymethylglutaryl-CoA reductase inhibitors, neuroprotection, propensity score, treatment outcome",
author = "John Whyte and Ketchum, {Jessica M.} and Jenny Bogner and Brunner, {Robert C.} and Flora Hammond and Ross Zafonte and Whiteneck, {Gale G.} and Alan Weintraub",
year = "2019",
month = "1",
day = "1",
doi = "10.1089/neu.2017.5545",
language = "English (US)",
volume = "36",
pages = "118--125",
journal = "Journal of Neurotrauma",
issn = "0897-7151",
publisher = "Mary Ann Liebert Inc.",
number = "1",

}

TY - JOUR

T1 - Effects of Statin Treatment on Outcomes after Traumatic Brain Injury

AU - Whyte, John

AU - Ketchum, Jessica M.

AU - Bogner, Jenny

AU - Brunner, Robert C.

AU - Hammond, Flora

AU - Zafonte, Ross

AU - Whiteneck, Gale G.

AU - Weintraub, Alan

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Neuroprotective treatments that have shown promise in reducing secondary injury and improving recovery in animal models of traumatic brain injury (TBI) have not been found effective to date in humans. One reason may be the delay after injury in initiating treatment. Statin medications are among the promising neuroprotective agents in animal models, and their presence in the bloodstream of many individuals at the time of injury might optimize their clinical impact. This observational study conducted by a subset of centers participating in the National Institute on Disability, Independent Living, and Rehabilitation Research (NIDILRR)-funded TBI Model System program sought to examine the effects of taking statin medication at the time injury on functional outcomes. Participants >50 years of age were prospectively enrolled during patient rehabilitation. Demographic data, cardiovascular history, and brain injury history were obtained through chart abstraction and interview. Prescription medication use in the year prior to enrollment was determined from a national pharmacy search service. Propensity scoring was used to create 49 pairs of participants who were well matched on demographic and clinical attributes but discordant for statin use. The treated and untreated participants did not differ on initial Glasgow Coma Score, time until commands were followed, duration of post-traumatic amnesia, or Functional Independence Measure (FIM) scores at rehabilitation admission, discharge, or 1 year post-injury, or on acute or rehabilitation hospital lengths of stay. Evidence of greater and lesser statin compliance was not associated with outcome. This study did not provide support for a clinically important benefit of statin use at the time of moderate to severe TBI.

AB - Neuroprotective treatments that have shown promise in reducing secondary injury and improving recovery in animal models of traumatic brain injury (TBI) have not been found effective to date in humans. One reason may be the delay after injury in initiating treatment. Statin medications are among the promising neuroprotective agents in animal models, and their presence in the bloodstream of many individuals at the time of injury might optimize their clinical impact. This observational study conducted by a subset of centers participating in the National Institute on Disability, Independent Living, and Rehabilitation Research (NIDILRR)-funded TBI Model System program sought to examine the effects of taking statin medication at the time injury on functional outcomes. Participants >50 years of age were prospectively enrolled during patient rehabilitation. Demographic data, cardiovascular history, and brain injury history were obtained through chart abstraction and interview. Prescription medication use in the year prior to enrollment was determined from a national pharmacy search service. Propensity scoring was used to create 49 pairs of participants who were well matched on demographic and clinical attributes but discordant for statin use. The treated and untreated participants did not differ on initial Glasgow Coma Score, time until commands were followed, duration of post-traumatic amnesia, or Functional Independence Measure (FIM) scores at rehabilitation admission, discharge, or 1 year post-injury, or on acute or rehabilitation hospital lengths of stay. Evidence of greater and lesser statin compliance was not associated with outcome. This study did not provide support for a clinically important benefit of statin use at the time of moderate to severe TBI.

KW - brain injuries

KW - hydroxymethylglutaryl-CoA reductase inhibitors

KW - neuroprotection

KW - propensity score

KW - treatment outcome

UR - http://www.scopus.com/inward/record.url?scp=85059101587&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059101587&partnerID=8YFLogxK

U2 - 10.1089/neu.2017.5545

DO - 10.1089/neu.2017.5545

M3 - Article

AN - SCOPUS:85059101587

VL - 36

SP - 118

EP - 125

JO - Journal of Neurotrauma

JF - Journal of Neurotrauma

SN - 0897-7151

IS - 1

ER -